Literature DB >> 7875269

Airways obstruction and two year survival in patients with severe alpha 1-antitrypsin deficiency.

N Seersholm1, A Dirksen, A Kok-Jensen.   

Abstract

Because of the limited number of donor organs available, the selection of patients for lung transplantation is crucial. One important issue in setting priorities is the life expectancy without transplantation. The purpose of this study was to estimate survival based on lung function, in alpha 1-antitrypsin deficient patients. Data from the Danish alpha 1-antitrypsin deficiency registry were analysed. The basic element of the analysis was two year intervals, characterized by date of spirometry and known mortality status 2 yrs later. We found a simple exponential relationship between lung function (forced expiratory volume one second (FEV1)) and two year survival on conservative treatment. The formula implies an almost 100% two year survival until FEV1 falls below one third of predicted normal; at this level two year mortality increases and will reach 50% at a FEV1 of 15% predicted. In conclusion, the two year mortality of emphysema patients due to alpha 1-antitrypsin deficiency increases exponentially with decreasing FEV1 and the results imply that only a few patients who underwent lung transplantation would have had a better two year prognosis without this procedure.

Entities:  

Mesh:

Year:  1994        PMID: 7875269

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  6 in total

Review 1.  Alpha-1 antitrypsin deficiency: a commonly overlooked cause of lung disease.

Authors:  Sarah K Brode; Simon C Ling; Kenneth R Chapman
Journal:  CMAJ       Date:  2012-07-03       Impact factor: 8.262

Review 2.  Natural history of emphysema.

Authors:  Omar A Minai; Joshua Benditt; Fernando J Martinez
Journal:  Proc Am Thorac Soc       Date:  2008-05-01

Review 3.  Long-term clinical outcomes following treatment with alpha 1-proteinase inhibitor for COPD associated with alpha-1 antitrypsin deficiency: a look at the evidence.

Authors:  Franck F Rahaghi; Marc Miravitlles
Journal:  Respir Res       Date:  2017-05-30

Review 4.  Hereditary alpha-1-antitrypsin deficiency and its clinical consequences.

Authors:  Laura Fregonese; Jan Stolk
Journal:  Orphanet J Rare Dis       Date:  2008-06-19       Impact factor: 4.123

Review 5.  Augmentation therapy for alpha-1 antitrypsin deficiency: towards a personalised approach.

Authors:  Robert A Stockley; Marc Miravitlles; Claus Vogelmeier
Journal:  Orphanet J Rare Dis       Date:  2013-09-24       Impact factor: 4.123

6.  Alpha-1 antitrypsin deficiency as a common treatable mechanism in chronic respiratory disorders and for conditions different from pulmonary emphysema? A commentary on the new European Respiratory Society statement.

Authors:  Andrea Gramegna; Stefano Aliberti; Marco Confalonieri; Angelo Corsico; Luca Richeldi; Carlo Vancheri; Francesco Blasi
Journal:  Multidiscip Respir Med       Date:  2018-10-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.